Nectar Lifesciences 

₹12.19
13
+₹0.02+0.16% Friday 09:59

統計

當日最高
12.49
當日最低
12.11
52週高點
22.4
52週低點
9.3
成交量
205,001
平均成交量
201,385
市值
2.73B
本益比
-
股息殖利率
-
股息
-

股息

0%股息殖利率
Sep 20
₹0.05
Oct 19
₹0.05
Oct 18
₹0.05
Oct 17
₹0.05
Oct 16
₹0.10
10年成長
不適用
5年成長
不適用
3年成長
不適用
1年成長
不適用

財報

27May預期
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
999
333
-333
-999
預期EPS
不適用
實際EPS
不適用

財務

-6.81%利潤率
未盈利
2019
2020
2021
2022
2023
2024
16.7B營收
-1.14B淨利

其他人也在關注

此清單是根據在 Stock Events 上追蹤 NECLIFE.NSE 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing services (CRAMS), encompassing process innovation, optimization, and validation, along with production scale-up. This includes the preparation and global submission of drug master files (DMFs) and certificates of suitability, multi-kilo pilot plant manufacturing, large-scale bulk production, and chiral resolution. The company also offers specialized services in chemical and analytical development, as well as providing analytical, manufacturing, and engineering consulting. NLL's product range features a variety of active pharmaceutical ingredients (APIs) and intermediates, prominently including numerous cephalosporin compounds like cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. Additionally, Nectar Lifesciences engages in contract manufacturing for finished dosage forms, producing items such as tablets, capsules, dry powder oral suspensions, granules, and injectables, particularly for cephalosporin medications. Beyond its core pharmaceutical offerings, the company also supplies diagnostic tools, empty hard gelatin capsules, and menthol products.
Show more...
執行長
Sanjiv Goyal
員工
111
國家
印度
ISIN
INE023H01027

上市

0 Comments

分享你的想法

FAQ

Nectar Lifesciences 今天的股價是多少?
NECLIFE.NSE 目前價格為 ₹12.19 INR,過去 24 小時上漲了 +0.16%。在圖表上更密切關注 Nectar Lifesciences 股價表現。
Nectar Lifesciences 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 NSE (India) 交易所,Nectar Lifesciences 的股票以代號 NECLIFE.NSE 進行交易。
Nectar Lifesciences 的股價在上漲嗎?
NECLIFE.NSE 股票較上週下跌 -2.4%,本月上漲 +15%,過去一年 Nectar Lifesciences 下跌 -16.33%。
Nectar Lifesciences 的市值是多少?
今天 Nectar Lifesciences 的市值為 2.73B
Nectar Lifesciences 去年的營收是多少?
Nectar Lifesciences 去年的營收為 16.7BINR。
Nectar Lifesciences 去年的淨利是多少?
NECLIFE.NSE 去年的淨收益為 -1.14BINR。
Nectar Lifesciences 會發放股息嗎?
是的,NECLIFE.NSE 的股息每 年度 發放一次。每股最新股息為 0.05 INR。截至今日,股息殖利率(FWD)% 為 0%。
Nectar Lifesciences 有多少名員工?
截至 September 05, 2026,公司共有 111 名員工。
Nectar Lifesciences 位於哪個產業?
Nectar Lifesciences從事於Health & Wellness產業。
Nectar Lifesciences 何時完成拆股?
Nectar Lifesciences 上次拆股發生於 November 12, 2008,比例為 10:1。
Nectar Lifesciences 的總部在哪裡?
Nectar Lifesciences 的總部位於 印度 的 Chandigarh。